AAP
TEVA icon

Ardsley Advisory Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Ardsley Advisory Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$880K – 171
2017
Q3 		$880K Hold
50,000
– – 0.12% 75
2017
Q2 		$1.66M Hold
50,000
– – 0.26% 71
2017
Q1 		$1.6M Buy
+50,000
New +$1.71M 0.25% 73

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return

Ardsley Advisory Partners's TEVA Position: Q2 2026 in Review

Ardsley Advisory Partners reduced its Teva Pharmaceuticals (TEVA) stake by 16% in Q2 2026, selling an estimated $3M and leaving 465,000 shares worth $15.8M. The position accounts for 1.64% of the portfolio, ranked #14.

Ardsley Advisory Partners first reported a position in TEVA in Q4 2015 and has held it in 12 quarters since. The position peaked at $18.1M in Q4 2025. 183 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ardsley Advisory Partners held 465,000 shares of Teva Pharmaceuticals worth $15.8M as of Q2 2026.
  • Ardsley Advisory Partners sold 90,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $3M.
  • Teva Pharmaceuticals made up 1.64% of Ardsley Advisory Partners's portfolio in Q2 2026, its #14 holding.
  • Ardsley Advisory Partners first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 12 quarters since.
  • Ardsley Advisory Partners's Teva Pharmaceuticals position peaked at $18.1M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.